Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 15/20 | 0.59 |
| ▸ | NPY1R | P25929 | 3/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16664545 | 0.80 | RORC (0.53) | RORCBTK | |
| SCHEMBL16851394 | 0.80 | RORC (0.53) | RORCBTK | |
| SCHEMBL8274769 | 0.75 | SCN9A (0.43) | RORCNPY1RKMT2AL3MBTL1 | |
| SCHEMBL5132571 | 0.75 | NPY1R (0.59) | NPY1RKMT2AL3MBTL1 | |
| SCHEMBL7416762 | 0.75 | NPY1R (0.59) | NPY1RKMT2AL3MBTL1 | |
| SCHEMBL29048164 | 0.75 | SMN1; SMN2 (0.57) | NPY1RKMT2AL3MBTL1 | |
| SCHEMBL16851207 | 0.74 | RORC (0.60) | RORCBTKKMT2AL3MBTL1 | |
| SCHEMBL16664605 | 0.74 | RORC (0.60) | RORCBTKKMT2AL3MBTL1 | |
| SCHEMBL16848680 | 0.74 | RORC (1.00) | RORC | |
| SCHEMBL16664546 | 0.73 | RORC (0.83) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745364-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190292159-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745364-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | RORB, RORA, RORC | RORC 3/4885NPY1R 76/4885BTK 912/4885 |
| US-20190292159-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | RORC 3/4885NPY1R 76/4885BTK 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.